Author information
1
Oregon Health & Science University, School of Public Health, Portland, Oregon, USA.
2
Oregon Health & Science University, School of Public Health, Division of Infectious Diseases Portland, Oregon, USA.
3
Oregon Medical Research, Portland, Oregon, USA.
4
Oregon Health & Science University, School of Public Health, Department of Dermatology, Portland, Oregon, USA.
Abstract
Exacerbation or reactivation of chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) in persons infected with psoriasis during treatment with biologics is a documented concern with use of tumor necrosis factor (TNF) inhibitors. Much less is known, however, about these risks in relation to newer biologic drugs including ustekinumab (interleukin (IL)-12/23 inhibition).